10 February 2020
Source: Fight for Sight
A leading Professor of Ophthalmology at the University of Oxford has shared the details of his research which could pave the way for a new treatment for sight loss condition Stargardt disease.
In the latest episode of eye research charity Fight for Sight’s podcast Eye Research Matters, Professor Robert MacLaren discusses his pioneering research into using gene therapy to treat the genetic eye condition, which involves using a harmless virus to take the correct genetic information into the eye so that it starts to work properly.
The gene therapy approach has been successful in other inherited eye diseases and is halting sight loss or even restoring some sight for patients at clinical trial. However, in Stargardt disease the faulty gene is so large it needs a bigger viral ‘package’ to hold the correct information and carry it into the affected cells.
Following early research funded by Fight for Sight, Professor MacLaren and his team at the University of Oxford have developed a larger viral ‘package’ to prove that it could successfully act as a vehicle for carrying the correct genetic information.
Professor MacLaren said: “We worked out a way of splitting the ABCA4 gene in two halves which overlap and recombine. In this research we were able to show that if we split the gene into two segments in a certain way, we could deliver it in two viral vectors. Imagine it like building a bridge over a river and the bridge is too big to fit on one lorry so you have to use two lorries. The issue is working out where to cut the bridge to make sure when you put it back together it’s stable.”
It’s hoped the new therapy can soon be taken to clinical trial and could ultimately lead to a new treatment that could transform the lives of people living with the disease by halting its progression.
Head of Research at Fight for Sight, Dr Rubina Ahmed said: “We know what a devastating impact Stargardt disease can have on people and their families and currently there is no cure, so this research has huge potential to transform lives. This work shows the possibilities of eye research to make significant breakthroughs and find new treatments, which is why Fight for Sight focuses on the early stage research that can lead to these sorts of opportunities. The only barrier is the funding to make breakthroughs happen, with only one percent of funding invested in eye research despite 20 percent of people being affected by sight loss or blindness.”
Stargardt disease causes progressive central sight loss and there is currently no cure. The condition is most often caused by a fault in a specific gene (ABCA4 gene).
On the podcast, Professor MacLaren also discusses his research into the inherited eye condition retinitis pigmentosa and the future of robot-assisted eye surgery.
To listen to the full show, search for Eye Research Matters on Apple Podcasts or follow the link.
Róisín Treacy, Media and Communications Officer, Direct line: 020 3828 2936; Mobile: 07921 828662; E-mail: email@example.com
Sarah Campion, Director of Communications and Marketing; Direct line: 020 7264 3910; Mobile: 07921 828662; Email: firstname.lastname@example.org
About Fight for Sight
Fight for Sight is the national charity dedicated to funding pioneering research to prevent sight loss and treat eye disease.
We currently invest in over a hundred and fifty research projects led by the leading researchers at 42 universities and hospitals across the country, and we campaign and lobby on important issues related to sight loss and blindness.
We cover the whole range of eye conditions, from the leading causes of blindness, like glaucoma, age-related macular degeneration and diabetic retinopathy to rare inherited eye disease.
Over the course of Fight for Sight’s history the charity’s achievements include:
- the creation of the corneal transplant service
- new treatments to save the sight of premature babies
- research leading to the world’s first clinical trial of gene therapy treatments for choroideremia, an inherited condition that causes blindness in men
- the design of a new eye test that can detect the early stages of sight loss in age-related macular degeneration
- the identification of new genes responsible for glaucoma, retinitis pigmentosa, keratoconus and other corneal disorders
- supporting the development of Peek, a Portable Eye Examination Kit that uses a unique smartphone-based system for eye testing anywhere in the world